In short
Clesrovimab (also known as MK-1654) is an investigational drug being studied for its potential to prevent respiratory syncytial virus (RSV) infections in infants. A clinical trial has been conducted to evaluate the safety, tolerability, and how the drug moves through the body (pharmacokinetics) in both pre-term and full-term infants. The study used different dosing levels to determine the optimal amount of medication while monitoring safety carefully. This article provides information about this clinical trial and what we know so far about clesrovimab's potential role in protecting vulnerable infants from RSV infections.
Key points
- Clesrovimab (MK-1654) is being investigated as a potential preventive treatment for respiratory syncytial virus (RSV) infections in infants. A clinical trial evaluated different doses of clesrovimab administered via intramuscular injection to both pre-term (29-35 weeks) and full-term (>35 weeks) infants. The study specifically measured safety outcomes including injection site reactions and systemic effects, as well as how long the drug remains in the infant's body. Researchers carefully escalated dosing only after confirming safety at each level. The study followed most participants for up to a year, with some followed for about 18 months, to understand the drug's long-term effects and persistence in the body. This research could potentially lead to a new preventive option for RSV, which poses significant risks to vulnerable infant populations.
At a glance
- Drug Name
- Clesrovimab (MK-1654)
- Clinical Trial ID
- NCT03524118
- Study Design
- Double-blind, randomized, placebo-controlled, single ascending dose study
- Target Conditions
- Respiratory Syncytial Virus (RSV), Respiratory Tract Infection
- Study Population
- Pre-term infants (born at 29 to 35 weeks) and full-term infants (born after 35 weeks)
- Administration Method
- Intramuscular (IM) injection
- Study Groups
- 7 active treatment panels (A, B, C, D1, D2, E1, E2) with ascending doses and 1 placebo group
- Follow-up Duration
- Up to 365 days for Panels A, B, C, D1, and E1; up to 545 days for Panels D2 and E2
- Primary Outcomes
- Safety measures: injection site reactions, systemic side effects, serious adverse events
- Secondary Outcomes
- Pharmacokinetic parameters (how the drug moves through the body) and development of anti-drug antibodies
What is Clesrovimab?
Clesrovimab, also known as MK-1654, is an investigational medication that is being studied for its potential to prevent respiratory infections, particularly those caused by Respiratory Syncytial Virus (RSV). It belongs to a class of medications known as monoclonal antibodies, which are laboratory-made proteins that mimic the immune system's ability to fight off harmful pathogens like viruses.
Medical Conditions Treated
Clesrovimab is being developed to help prevent and treat respiratory tract infections, with a specific focus on those caused by Respiratory Syncytial Virus (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms. However, it can be serious, especially for infants and older adults. RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States.
How Clesrovimab is Administered
According to the clinical trial information, clesrovimab is administered as a single dose via intramuscular (IM) injection. This means the medication is injected directly into a muscle, which allows for slow absorption into the bloodstream. This administration method is commonly used for medications that need to remain in the body for an extended period.
Clinical Trial Information
Clesrovimab is currently being studied in clinical trials to evaluate its safety, tolerability, and effectiveness. One specific study (identified as MK-1654-002) is a double-blind, randomized, placebo-controlled, single ascending dose study involving pre-term and full-term infants.
The study includes several different groups:
- Pre-term infants (born at 29 to 35 weeks gestational age) receiving different doses of clesrovimab
- Full-term infants (born at more than 35 weeks gestational age) receiving clesrovimab
- A control group receiving a placebo (a solution of 0.9% sodium chloride, which has no medicinal effect)
The trial is designed with multiple panels (labeled A through E) to test different doses of the medication, with safety reviews conducted after each panel before proceeding to the next higher dose. This approach, known as a dose escalation design, helps researchers determine the optimal dose that provides the desired effect with minimal side effects.
Participants in the study are monitored for up to 365 days (1 year) or 545 days (approximately 1.5 years) depending on when they enrolled in the study.
Safety Monitoring
The clinical trial for clesrovimab carefully monitors participants for safety concerns. This includes tracking:
- Injection site adverse events - reactions that occur at the location where the medication was injected, such as pain, redness, or swelling
- Systemic adverse events - reactions that affect the whole body, such as fever or allergic reactions
- Serious adverse events (SAEs) - significant medical events that may require hospitalization or medical intervention
In the study, these adverse events are monitored closely, particularly during the first 5 days after receiving the injection.
How Clesrovimab Works in the Body
The clinical trial is collecting detailed information about how clesrovimab behaves in the body, known as pharmacokinetics. This includes measuring:
- Maximum serum concentration (Cmax) - the highest level of medication in the bloodstream
- Time to maximum serum concentration (Tmax) - how long it takes to reach the highest level
- Half-life (t1/2) - the time it takes for half of the medication to be cleared from the body
- Area under the curve (AUC) - a measure of the total exposure to the medication over time
The researchers are checking the levels of clesrovimab in participants' blood at specific time points: 7 days, 14 days, 90 days, 150 days, and 365 days after injection. This helps them understand how long the medication remains in the body and at what levels, which is important for determining how often it would need to be administered to provide protection against RSV.
The study is also monitoring for the development of anti-drug antibodies (ADAs). These are antibodies produced by the body against the medication itself, which could potentially reduce its effectiveness. Understanding whether patients develop these antibodies is important for evaluating the long-term usefulness of clesrovimab.
Potential Side Effects
As clesrovimab is still in clinical trials, the complete profile of potential side effects is not yet fully established. The current trial is specifically designed to gather information about possible adverse reactions, both at the injection site and throughout the body.
Common side effects with monoclonal antibody medications similar to clesrovimab may include:
- Injection site reactions (pain, redness, swelling)
- Fever
- Headache
- Muscle pain
- Fatigue
The clinical trial is carefully monitoring participants for any unexpected or serious side effects to ensure the safety of this investigational medication.